Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.63 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.57 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.55 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4857969 | 0.94 | MAP2K1 (0.56) | MAP2K1MAP2K2MAP2K5EIF2AK1MEN1 | |
| SCHEMBL4860195 | 0.92 | MAP2K1 (0.53) | MAP2K1MAP2K2MAP2K5EIF2AK1MEN1 | |
| SCHEMBL4860487 | 0.92 | MAP2K1 (0.68) | MAP2K1MAP2K2MAP2K5EIF2AK1KCNH2 | |
| SCHEMBL4861972 | 0.91 | MAP2K1 (0.66) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL4861697 | 0.91 | MAP2K1 (0.57) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL7051234 | 0.90 | MAP2K1 (0.54) | MAP2K1MAP2K2MAP2K5EIF2AK1KCNH2 | |
| SCHEMBL4862521 | 0.89 | MAP2K1 (0.51) | MAP2K1MAP2K2MAP2K5EIF2AK1MEN1 | |
| SCHEMBL4862342 | 0.89 | MAP2K1 (0.51) | MAP2K1MAP2K2MAP2K5EIF2AK1MEN1 | |
| SCHEMBL4860053 | 0.89 | MAP2K1 (0.51) | MAP2K1MAP2K2MAP2K5EIF2AK1MEN1 | |
| SCHEMBL4862771 | 0.88 | MAP2K1 (0.50) | MAP2K1MAP2K2MAP2K5EIF2AK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1301472-B1 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER LAMBERT CO (US) | 2014-03-26 | — | — | EP | disclosed |
| US-7411001-B2 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-6960614-B2 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2005-08-11 | — | — | US | disclosed |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2004-03-18 | — | — | US | disclosed |
| EP-1301472-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002006213-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | CYP4X1, CYP2A7, CYP4B1 | MAP2K1 4341/4885MAP2K2 4268/4885MAP2K5 3605/4885 |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | CYP4X1, ALOX5, HAAO | MAP2K1 4312/4885MAP2K2 4025/4885MAP2K5 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.